White House Abandons Heidi Overton’s FDA Nomination Amid Senate Fractures

The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration (FDA) on Tuesday, just hours before a scheduled Senate committee vote. Overton, a physician and domestic policy adviser, lacked the necessary Republican support to advance. Her candidacy faced opposition from moderate Republicans over vaccine and vaping policies, as well as from Democrats and pro-life groups over her anti-abortion stance. The FDA will remain under acting leadership, with Republicans unlikely to confirm a permanent commissioner before Democrats take control of the Senate in January.
Key points
- The White House pulled Overton’s nomination late Tuesday, citing insufficient support among Senate Republicans, according to multiple sources.
- Overton was nominated in August to replace Marty Makary, who resigned in May after disputes over flavored vapes and vaccine policies.
- Senate Health Committee Chair Bill Cassidy remained undecided, stating he had questions about her scientific independence and support for breaking up combination vaccines.
- Overton faced opposition from Democrats and pro-life groups over her 2023 policy brief criticizing mifepristone and abortion pill access.
- The FDA is currently led by acting commissioner Kyle Diamantas, and Republicans are unlikely to confirm a new nominee before losing Senate control in January.
Background
Overton’s nomination followed a tumultuous year at the FDA under Commissioner Marty Makary, who resigned in May 2025 amid conflicts with the White House over flavored vapes and vaccine policies. The agency has lost over 4,500 staff in the past year. Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, was seen as a stabilizing loyalist but faced bipartisan scrutiny. Her nomination coincided with a broader push by the Trump administration to confirm nominees before Republicans lose control of the Senate in January, following midterm losses in November 2025.
How outlets are covering it
The Guardian and The New York Times emphasized the lack of Republican support as the primary reason for the withdrawal, noting that Overton needed all 12 Republican votes on the Senate Health, Education, Labor and Pensions Committee. CNN highlighted internal rifts, describing Overton’s relationship with Health and Human Services Secretary Robert F. Kennedy Jr. as 'icy' and noting her role in stalling 'Make America Healthy Again' policies. CNBC focused on the political fallout, citing the White House’s consideration of former Senator Roger Marshall as a replacement, though his support for Kennedy’s vaccine-skeptical policies may complicate confirmation. Cassidy, in a post on X, argued the White House abandoned a 'viable confirmation path' and that pro-life senators sought assurances on abortion policies that the administration refused to provide. Reproductive rights groups, including Reproductive Freedom for All, celebrated the withdrawal, citing Overton’s 2023 policy brief opposing mifepristone access. Meanwhile, a nonpartisan group, Health in Office, launched a campaign branding Overton 'Heidi Vaperton' over her defense of fruit-flavored vapes, which she argued could help adults quit smoking.
Why it matters
The withdrawal leaves the FDA without a permanent leader, exacerbating staffing shortages and policy uncertainty. It highlights the Trump administration’s struggle to confirm nominees amid bipartisan opposition and internal divisions between 'Make America Healthy Again' advocates and traditional conservatives. The move also signals the difficulty of advancing controversial health policies, such as vaccine restrictions and abortion pill regulation, in a polarized political environment. With Democrats set to take control of the Senate in January, the FDA may remain under acting leadership for an extended period, potentially delaying critical regulatory decisions.
What to watch
The White House is weighing former Senator Roger Marshall as a potential replacement, though his support for Kennedy’s vaccine-skeptical policies may face similar opposition. Republicans are unlikely to confirm a permanent FDA commissioner before losing Senate control in January, according to Cassidy. The FDA will continue under acting leadership, with Kyle Diamantas serving as acting commissioner. The agency’s safety review of mifepristone is expected to conclude by March 2027, but regulatory decisions may be delayed due to the lack of a permanent commissioner.
- White House withdraws nomination of Heidi Overton to lead FDA The Guardian
- White House Withdraws Nomination of Heidi Overton to Be F.D.A. Commissioner The New York Times
- White House drops Trump’s FDA pick amid senators’ opposition and ‘icy’ relationship with RFK Jr. CNN
- White House pulls nomination of Heidi Overton to lead Food and Drug Administration – as it happened The Guardian
- Trump withdraws Heidi Overton as nominee to lead Food and Drug Administration, sources say CNBC
Want the full story? Read the original reporting
Read on The Guardian